FDA Issues CRL for Vatiquinone in Friedreich Ataxia, Requests More Efficacy Data

Today, the FDA issued a complete response letter (CRL) for vatiquinone (PTC Therapeutics), delaying its potential approval as a treatment for Friedreich ataxia amid efficacy concerns.